FDA accepts reduced sample size for X4’s 4WARD Phase 3
X4 Pharmaceuticals said the FDA agreed to reduce 4WARD Phase 3 to 126 patients, accepted the proposed safety database, and the company targets enrollment completion by year-end 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.